{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T02:25:32Z","timestamp":1791685532647,"version":"4.3.4"},"reference-count":56,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,11,18]],"date-time":"2016-11-18T00:00:00Z","timestamp":1479427200000},"content-version":"vor","delay-in-days":170,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1038\/mt.2016.53","type":"journal-article","created":{"date-parts":[[2016,3,7]],"date-time":"2016-03-07T07:26:13Z","timestamp":1457335573000},"page":"1019-1029","source":"Crossref","is-referenced-by-count":101,"title":["CNS-accessible Inhibitor of Glucosylceramide Synthase for Substrate Reduction Therapy of Neuronopathic Gaucher Disease"],"prefix":"10.1016","volume":"24","author":[{"given":"John","family":"Marshall","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh S","family":"Bangari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Budman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyejung","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer B","family":"Nietupski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Allaire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary A","family":"Cromwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory A","family":"Grabowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P","family":"Leonard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seng H","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/mt.2016.53_bib1","series-title":"The Online Metabolic and Molecular Bases of Inherited Disease","article-title":"Gaucher disease","author":"Grabowski","year":"2010"},{"key":"10.1038\/mt.2016.53_bib2","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0002-9343(02)01150-6","article-title":"Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry","volume":"113","author":"Weinreb","year":"2002","journal-title":"Am J Med"},{"key":"10.1038\/mt.2016.53_bib3","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1097\/GIM.0b013e31818e2c19","article-title":"Dose\u2013response relationships for enzyme replacement therapy with imiglucerase\/alglucerase in patients with Gaucher disease type 1","volume":"11","author":"Grabowski","year":"2009","journal-title":"Genet Med"},{"key":"10.1038\/mt.2016.53_bib4","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1023\/A:1025902113005","article-title":"The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement","volume":"26","author":"Cox","year":"2003","journal-title":"J Inherit Metab Dis"},{"key":"10.1038\/mt.2016.53_bib5","doi-asserted-by":"crossref","DOI":"10.1517\/21678707.2014.899148","article-title":"A systematic review on effectiveness and safety of eliglustat for type 1 Gaucher disease","author":"Smid","year":"2014","journal-title":"Expert Opinion on Orphan Drugs"},{"key":"10.1038\/mt.2016.53_bib6","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ymgme.2014.11.008","article-title":"The clinical management of Type 2 Gaucher disease","volume":"114","author":"Weiss","year":"2015","journal-title":"Mol Genet Metab"},{"key":"10.1038\/mt.2016.53_bib7","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s10545-007-0577-z","article-title":"Outcome of type III Gaucher disease on enzyme replacement therapy: review of 55 cases","volume":"30","author":"Davies","year":"2007","journal-title":"J Inherit Metab Dis"},{"key":"10.1038\/mt.2016.53_bib8","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s10545-011-9347-z","article-title":"Four-year follow-up of chronic neuronopathic Gaucher disease in Europeans using a modified severity scoring tool","volume":"34","author":"Davies","year":"2011","journal-title":"J Inherit Metab Dis"},{"key":"10.1038\/mt.2016.53_bib9","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s10545-007-0783-8","article-title":"No justification for very high-dose enzyme therapy for patients with type III Gaucher disease","volume":"30","author":"Zimran","year":"2007","journal-title":"J Inherit Metab Dis"},{"key":"10.1038\/mt.2016.53_bib10","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ymgme.2014.08.011","article-title":"CNS, lung, and lymph node involvement in Gaucher disease type 3 after 11 years of therapy: clinical, histopathologic, and biochemical findings","volume":"114","author":"Burrow","year":"2015","journal-title":"Mol Genet Metab"},{"key":"10.1038\/mt.2016.53_bib11","first-page":"425","article-title":"Cerebrospinal fluid infusion of alglucerase in the treatment of acute neuronopathic Gaucher's disease","volume":"38","author":"Bembi","year":"2005","journal-title":"Pediatr. Res"},{"key":"10.1038\/mt.2016.53_bib12","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1212\/01.wnl.0000247744.10990.e6","article-title":"Image-guided, direct convective delivery of glucocerebrosidase for neuronopathic Gaucher disease","volume":"68","author":"Lonser","year":"2007","journal-title":"Neurology"},{"key":"10.1038\/mt.2016.53_bib13","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1097\/00007890-199503000-00011","article-title":"Ten years' experience of bone marrow transplantation for Gaucher disease","volume":"59","author":"Ringd\u00e9n","year":"1995","journal-title":"Transplantation"},{"key":"10.1038\/mt.2016.53_bib14","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3109\/08880018.2013.793757","article-title":"Allogeneic hematopoietic stem cell transplantation for treatment of Gaucher disease","volume":"30","author":"Machaczka","year":"2013","journal-title":"Pediatr Hematol Oncol"},{"key":"10.1038\/mt.2016.53_bib15","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3892\/ijmm.2012.1187","article-title":"New strategies for the treatment of lysosomal storage diseases (review)","volume":"31","author":"Parenti","year":"2013","journal-title":"Int J Mol Med"},{"key":"10.1038\/mt.2016.53_bib16","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1002\/cmdc.201300327","article-title":"Glucosylceramide mimics: highly potent GCase inhibitors and selective pharmacological chaperones for mutations associated with types 1 and 2 Gaucher disease","volume":"8","author":"Sch\u00f6nemann","year":"2013","journal-title":"ChemMedChem"},{"key":"10.1038\/mt.2016.53_bib17","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/ana.21491","article-title":"Randomized, controlled trial of miglustat in Gaucher's disease type 3","volume":"64","author":"Schiffmann","year":"2008","journal-title":"Ann Neurol"},{"key":"10.1038\/mt.2016.53_bib18","article-title":"A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1","author":"Lukina","year":"2010","journal-title":"Blood"},{"key":"10.1038\/mt.2016.53_bib19","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ymgme.2007.04.001","article-title":"A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease","volume":"91","author":"McEachern","year":"2007","journal-title":"Mol Genet Metab"},{"key":"10.1038\/mt.2016.53_bib20","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s10545-010-9072-z","article-title":"Improved management of lysosomal glucosylceramide levels in a mouse model of type 1 Gaucher disease using enzyme and substrate reduction therapy","volume":"33","author":"Marshall","year":"2010","journal-title":"J Inherit Metab Dis"},{"key":"10.1038\/mt.2016.53_bib21","doi-asserted-by":"crossref","first-page":"e43310","DOI":"10.1371\/journal.pone.0043310","article-title":"Systemic delivery of a glucosylceramide synthase inhibitor reduces CNS substrates and increases lifespan in a mouse model of type 2 Gaucher disease","volume":"7","author":"Cabrera-Salazar","year":"2012","journal-title":"PLoS One"},{"key":"10.1038\/mt.2016.53_bib22","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2119\/molmed.2015.00088","article-title":"Efficacy of enzyme and substrate reduction therapy with a novel antagonist of glucosylceramide synthase for fabry disease","volume":"21","author":"Ashe","year":"2015","journal-title":"Mol Med"},{"key":"10.1038\/mt.2016.53_bib23","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3109\/08880018.2012.762076","article-title":"Gauchers disease\u2014a reappraisal of hematopoietic stem cell transplantation","volume":"30","author":"Ito","year":"2013","journal-title":"Pediatr Hematol Oncol"},{"key":"10.1038\/mt.2016.53_bib24","doi-asserted-by":"crossref","first-page":"23815","DOI":"10.1074\/jbc.M502799200","article-title":"X-ray structure of human acid-beta-glucosidase covalently bound to conduritol-B-epoxide. Implications for Gaucher disease","volume":"280","author":"Premkumar","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1038\/mt.2016.53_bib25","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0006-291X(75)90286-7","article-title":"The Gaucher mouse","volume":"67","author":"Kanfer","year":"1975","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1038\/mt.2016.53_bib26","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1111\/j.1471-4159.1978.tb12395.x","article-title":"The Gaucher mouse: differential action of conduritol B epoxide and reversibility of its effects","volume":"30","author":"Stephens","year":"1978","journal-title":"J Neurochem"},{"key":"10.1038\/mt.2016.53_bib27","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ymgme.2008.01.013","article-title":"Dependence of reversibility and progression of mouse neuronopathic Gaucher disease on acid beta-glucosidase residual activity levels","volume":"94","author":"Xu","year":"2008","journal-title":"Mol Genet Metab"},{"key":"10.1038\/mt.2016.53_bib28","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.gene.2013.09.072","article-title":"Uncoupling of osteoblast-osteoclast regulation in a chemical murine model of Gaucher disease","volume":"532","author":"Mucci","year":"2013","journal-title":"Gene"},{"key":"10.1038\/mt.2016.53_bib29","doi-asserted-by":"crossref","first-page":"26052","DOI":"10.1074\/jbc.M113.463562","article-title":"\u03b2-Glucosidase 2 (GBA2) activity and imino sugar pharmacology","volume":"288","author":"Ridley","year":"2013","journal-title":"J Biol Chem"},{"key":"10.1038\/mt.2016.53_bib30","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1093\/hmg\/ddp580","article-title":"Neuronopathic Gaucher disease in the mouse: viable combined selective saposin C deficiency and mutant glucocerebrosidase (V394L) mice with glucosylsphingosine and glucosylceramide accumulation and progressive neurological deficits","volume":"19","author":"Sun","year":"2010","journal-title":"Hum Mol Genet"},{"key":"10.1038\/mt.2016.53_bib31","first-page":"627","article-title":"The Gaucher mouse","volume":"95","author":"Kanfer","year":"1982","journal-title":"Prog Clin Biol Res"},{"key":"10.1038\/mt.2016.53_bib32","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1002\/jnr.22371","article-title":"A mutation in the saposin C domain of the sphingolipid activator protein (Prosaposin) gene causes neurodegenerative disease in mice","volume":"88","author":"Yoneshige","year":"2010","journal-title":"J Neurosci Res"},{"key":"10.1038\/mt.2016.53_bib33","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.expneurol.2010.11.019","article-title":"Relationship between neuropathology and disease progression in the SOD1(G93A) ALS mouse","volume":"227","author":"Yang","year":"2011","journal-title":"Exp Neurol"},{"key":"10.1038\/mt.2016.53_bib34","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/hmg\/10.2.137","article-title":"Neurological abnormalities in a knock-in mouse model of Huntington's disease","volume":"10","author":"Lin","year":"2001","journal-title":"Hum Mol Genet"},{"key":"10.1038\/mt.2016.53_bib35","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1517\/14728222.2014.981530","article-title":"Emerging therapeutic targets for Gaucher disease","volume":"19","author":"Vitner","year":"2015","journal-title":"Expert Opin Ther Targets"},{"key":"10.1038\/mt.2016.53_bib36","doi-asserted-by":"crossref","first-page":"e19037","DOI":"10.1371\/journal.pone.0019037","article-title":"Isofagomine in vivo effects in a neuronopathic Gaucher disease mouse","volume":"6","author":"Sun","year":"2011","journal-title":"PLoS One"},{"key":"10.1038\/mt.2016.53_bib37","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1517\/13543776.2011.569162","article-title":"Pharmacological chaperone therapy for Gaucher disease: a patent review","volume":"21","author":"Benito","year":"2011","journal-title":"Expert Opin Ther Pat"},{"key":"10.1038\/mt.2016.53_bib38","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.expneurol.2010.07.023","article-title":"Intracerebroventricular delivery of glucocerebrosidase reduces substrates and increases lifespan in a mouse model of neuronopathic Gaucher disease","volume":"225","author":"Cabrera-Salazar","year":"2010","journal-title":"Exp Neurol"},{"key":"10.1038\/mt.2016.53_bib39","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1242\/dmm.008185","article-title":"Animal models for Gaucher disease research","volume":"4","author":"Farfel-Becker","year":"2011","journal-title":"Dis Model Mech"},{"key":"10.1038\/mt.2016.53_bib40","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.bbalip.2014.02.008","article-title":"From sheep to mice to cells: tools for the study of the sphingolipidoses","volume":"1841","author":"Zigdon","year":"2014","journal-title":"Biochim Biophys Acta"},{"key":"10.1038\/mt.2016.53_bib41","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1006\/mthe.2002.0650","article-title":"Demonstration of feasibility of in vivo gene therapy for Gaucher disease using a chemically induced mouse model","volume":"6","author":"Marshall","year":"2002","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2016.53_bib42","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/nm.3449","article-title":"RIPK3 as a potential therapeutic target for Gaucher's disease","volume":"20","author":"Vitner","year":"2014","journal-title":"Nat Med"},{"key":"10.1038\/mt.2016.53_bib43","doi-asserted-by":"crossref","first-page":"e57560","DOI":"10.1371\/journal.pone.0057560","article-title":"Substrate compositional variation with tissue\/region and Gba1 mutations in mouse models\u2013implications for Gaucher disease","volume":"8","author":"Sun","year":"2013","journal-title":"PLoS One"},{"key":"10.1038\/mt.2016.53_bib44","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/0304-4165(79)90133-8","article-title":"Destruction and resynthesis of mouse beta-glucosidases","volume":"582","author":"Hara","year":"1979","journal-title":"Biochim Biophys Acta"},{"key":"10.1038\/mt.2016.53_bib45","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s12017-010-8114-x","article-title":"The role of the ceramide acyl chain length in neurodegeneration: involvement of ceramide synthases","volume":"12","author":"Ben-David","year":"2010","journal-title":"Neuromolecular Med"},{"key":"10.1038\/mt.2016.53_bib46","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1203\/00006450-200008000-00018","article-title":"Glucosylsphingosine accumulation in mice and patients with type 2 Gaucher disease begins early in gestation","volume":"48","author":"Orvisky","year":"2000","journal-title":"Pediatr Res"},{"key":"10.1038\/mt.2016.53_bib47","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.nbd.2003.08.016","article-title":"Toxicity of glucosylsphingosine (glucopsychosine) to cultured neuronal cells: a model system for assessing neuronal damage in Gaucher disease type 2 and 3","volume":"14","author":"Schueler","year":"2003","journal-title":"Neurobiol Dis"},{"key":"10.1038\/mt.2016.53_bib48","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1471-4159.1982.tb07950.x","article-title":"Accumulation of glucosylceramide and glucosylsphingosine (psychosine) in cerebrum and cerebellum in infantile and juvenile Gaucher disease","volume":"39","author":"Nilsson","year":"1982","journal-title":"J Neurochem"},{"key":"10.1038\/mt.2016.53_bib49","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S1096-7192(02)00117-8","article-title":"Glucosylsphingosine accumulation in tissues from patients with Gaucher disease: correlation with phenotype and genotype","volume":"76","author":"Orvisky","year":"2002","journal-title":"Mol Genet Metab"},{"key":"10.1038\/mt.2016.53_bib50","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1093\/hmg\/ddt468","article-title":"Neuronal accumulation of glucosylceramide in a mouse model of neuronopathic Gaucher disease leads to neurodegeneration","volume":"23","author":"Farfel-Becker","year":"2014","journal-title":"Hum Mol Genet"},{"key":"10.1038\/mt.2016.53_bib51","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1093\/brain\/aws095","article-title":"Contribution of brain inflammation to neuronal cell death in neuronopathic forms of Gaucher's disease","volume":"135","author":"Vitner","year":"2012","journal-title":"Brain"},{"key":"10.1038\/mt.2016.53_bib52","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ymgme.2009.12.006","article-title":"Miglustat in adult and juvenile patients with Niemann\u2013Pick disease type C: long-term data from a clinical trial","volume":"99","author":"Wraith","year":"2010","journal-title":"Mol Genet Metab"},{"key":"10.1038\/mt.2016.53_bib53","doi-asserted-by":"crossref","first-page":"e22410","DOI":"10.1371\/journal.pone.0022410","article-title":"The saccadic and neurological deficits in type 3 Gaucher disease","volume":"6","author":"Benko","year":"2011","journal-title":"PLoS One"},{"key":"10.1038\/mt.2016.53_bib54","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1023\/A:1015137917508","article-title":"Glycolipid analysis of different tissues and cerebrospinal fluid in type II Gaucher disease","volume":"25","author":"Gornati","year":"2002","journal-title":"J Inherit Metab Dis"},{"key":"10.1038\/mt.2016.53_bib55","doi-asserted-by":"crossref","first-page":"e0120194","DOI":"10.1371\/journal.pone.0120194","article-title":"Identification of a biomarker in cerebrospinal fluid for neuronopathic forms of Gaucher disease","volume":"10","author":"Zigdon","year":"2015","journal-title":"PLoS One"},{"key":"10.1038\/mt.2016.53_bib56","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1093\/hmg\/ddt057","article-title":"Atp13a2-deficient mice exhibit neuronal ceroid lipofuscinosis, limited \u03b1-synuclein accumulation and age-dependent sensorimotor deficits","volume":"22","author":"Schultheis","year":"2013","journal-title":"Hum Mol Genet"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001616303690?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001616303690?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T04:49:18Z","timestamp":1567658958000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001616303690"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":56,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["S1525001616303690"],"URL":"https:\/\/doi.org\/10.1038\/mt.2016.53","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]}}}